BlueCrest Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

BlueCrest Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-28,242	Closed	-$3.99M	–	870
2016 Q2	$3.99M	Buy	+28,242	New	+$4.16M	0.17%	143
2016 Q1	–	Sell	-18,835	Closed	-$2.65M	–	955
2015 Q4	$2.65M	Buy	18,835 +17,281	+1,112%	+$2.39M	0.11%	212
2015 Q3	$206K	Buy	+1,554	New	+$268K	0.01%	794
2014 Q4	–	Sell	-6,250	Closed	-$1M	–	617
2014 Q3	$1M	Buy	+6,250	New	+$961K	0.04%	335

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlueCrest Capital Management's JAZZ Position: Q3 2016 in Review

BlueCrest Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2016, closing a stake of 28,242 shares — an estimated $3.99M sold.

BlueCrest Capital Management first reported a position in JAZZ in Q3 2014 and held it in 4 quarters. The position peaked at $3.99M in Q2 2016. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

BlueCrest Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
BlueCrest Capital Management sold 28,242 Jazz Pharmaceuticals shares in Q3 2016, an estimated $3.99M.
BlueCrest Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2014 and held it in 4 quarters.
BlueCrest Capital Management's Jazz Pharmaceuticals position peaked at $3.99M in Q2 2016.
325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on BlueCrest Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.